Integra LifeSciences (NASDAQ:IART) Sets New 12-Month Low at $27.18

Integra LifeSciences Holdings Co. (NASDAQ:IART) reached a new 52-week low during trading on Thursday . The stock traded as low as $27.18 and last traded at $27.27, with a volume of 657051 shares traded. The stock had previously closed at $29.38.

Wall Street Analysts Forecast Growth

IART has been the topic of several recent analyst reports. Truist Financial decreased their target price on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research note on Friday, March 1st. JMP Securities decreased their target price on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research note on Thursday, February 29th. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price on the stock in a research note on Wednesday, April 3rd. Finally, StockNews.com downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $44.89.

Integra LifeSciences Trading Down 0.2 %

The firm has a market cap of $2.23 billion, a P/E ratio of 34.14, a P/E/G ratio of 0.86 and a beta of 1.12. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The stock has a 50 day simple moving average of $35.34 and a 200-day simple moving average of $38.76.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The company had revenue of $397.00 million during the quarter, compared to analysts’ expectations of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. Integra LifeSciences’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.94 EPS. On average, equities research analysts expect that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of Integra LifeSciences by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after purchasing an additional 72,294 shares during the period. Capital Research Global Investors boosted its holdings in Integra LifeSciences by 40.1% during the 4th quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company’s stock valued at $187,149,000 after acquiring an additional 1,228,996 shares during the period. Cooke & Bieler LP boosted its holdings in Integra LifeSciences by 4.4% during the 4th quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock valued at $123,447,000 after acquiring an additional 120,410 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Integra LifeSciences by 4.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock valued at $70,340,000 after acquiring an additional 63,323 shares during the period. Finally, Victory Capital Management Inc. boosted its holdings in Integra LifeSciences by 19.5% during the 3rd quarter. Victory Capital Management Inc. now owns 1,465,115 shares of the life sciences company’s stock valued at $55,953,000 after acquiring an additional 238,816 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.